SCHEMBL23227397

SCHEMBL23227397

COc1ccc(Cl)c(Cl)c1C1CCN(C(=O)[C@H]2COC(C)(C)N2C(=O)OC(C)(C)C)C(CO)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.38
SPHK1 Q9NYA1 1/20 0.36
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
HTR2B P41595 2/20 0.35
EPHA2 P29317 3/20 0.32
EPHB4 P54760 3/20 0.32
MAPT P10636 3/20 0.32
KDR P35968 2/20 0.32
PDE4B Q07343 2/20 0.32
DRD2 P14416 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ERBB2 P04626 2/20 0.32
ALDH1A1 P00352 2/20 0.31
MAPK1 P28482 1/20 0.31
GPR35 Q9HC97 1/20 0.31
GPR55 Q9Y2T6 1/20 0.31
HSD11B2 P80365 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217015 0.90 HTR2A (0.36) HTR2AHTR2CHTR2BDRD2
SCHEMBL23227396 0.89 BRD4 (0.38) BRD4SPHK1HTR2AHTR2CHTR2B
SCHEMBL29845081 0.88 BRD4 (0.38) BRD4SPHK1HTR2AHTR2CHTR2B
SCHEMBL23227515 0.84 HTR2A (0.42) HTR2AHTR2CHTR2BEPHA2EPHB4
SCHEMBL29844996 0.84 HTR2A (0.42) HTR2AHTR2CHTR2BEPHA2EPHB4
SCHEMBL29845074 0.79 HTR2A (0.43) HTR2AHTR2CHTR2BDRD2ALDH1A1
SCHEMBL23217079 0.79 HTR2A (0.43) HTR2AHTR2CHTR2BDRD2ALDH1A1
SCHEMBL23227208 0.78 HTR2A (0.44) HTR2AHTR2CHTR2BPDE4BSUV39H2
SCHEMBL23217128 0.78 HTR2A (0.34) HTR2AHTR2CHTR2BDRD2
SCHEMBL23217353 0.77 HTR2A (0.32) HTR2AHTR2CHTR2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 BRD4 497/4885SPHK1 517/4885HTR2A 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.